Suprasellar arachnoid cysts are uncommon collections of cerebrospinal fluid that arise from developmental splitting or duplication of arachnoid membranes, the delicate cobweb-like layers that envelop the brain. They cluster in the suprasellar region, the crowded crossroads at the base of the brain where the optic nerves cross, the hypothalamus and pituitary gland regulate hormones, and the fluid pathways of the third ventricle drain. Although arachnoid cysts as a group are rare, the suprasellar variety makes up a disproportionately large share of them in children, accounting for up to 21 percent of pediatric arachnoid cysts in reported series compared with roughly 9 percent in adults. Their location explains their danger: even a slowly growing, non-cancerous cyst can obstruct the foramina of Monro, the narrow channels through which fluid exits the lateral ventricles, triggering obstructive hydrocephalus, compress the optic apparatus, and distort the hypothalamic–pituitary axis.

What makes this boy’s story medically remarkable is the dissociation between what his body showed and what his brain was enduring. When clinicians examined him, his visual acuity was a perfect 10/10 in both eyes, his pupils reacted normally, and his eye movements were full. Yet fundoscopic examination, the simple act of looking into the back of the eye, revealed bilateral optic disc pallor, a whitening of the optic nerve head that signals chronic injury. The MRI added more evidence of long-standing trouble: dilated optic nerve sheaths consistent with raised intracranial pressure, massively enlarged lateral ventricles, and displacement of the circle of Willis arteries and the floor of the third ventricle. In other words, the boy’s visual system had been silently damaged for years even as his central vision held on, a phenomenon the authors attribute to partial optic atrophy with relative sparing of the papillomacular fibers that carry sharp central vision.

This clinical–radiological mismatch carries a sobering lesson for pediatricians and ophthalmologists everywhere. Preserved visual acuity, the authors argue, should never be used as the sole measure of optic nerve health in patients with signs of chronic intracranial hypertension. Formal automated perimetry, which maps the full visual field, and optical coherence tomography, which measures the thickness of the nerve fiber layer, can reveal functional and structural damage long before a patient notices anything wrong. In this case, neither tool was available in the child’s resource-limited local setting, and bedside confrontation testing of visual fields showed no gross deficit. Earlier access to magnetic resonance imaging could potentially have identified the obstructive hydrocephalus before optic disc pallor ever developed, and the authors suggest that the insidious nature of gait imbalance, combined with the absence of headache, seizures, visual complaints, or endocrine symptoms, allowed the diagnosis to slip further away with each passing year.

The surgical answer to this problem was as elegant as the anatomy was daunting. Rather than opening the skull or implanting a permanent shunt, the team performed a neuroendoscopic ventriculocystocisternostomy, a minimally invasive procedure in which a rigid endoscope is threaded through a small burr hole at Kocher’s point near the top of the skull. Navigating by familiar landmarks, the choroid plexus, the septal structures, and the foramen of Monro, the surgeon reached the dome of the cyst and widely fenestrated its apical membrane, opening a communication between the lateral ventricle and the cyst cavity. The endoscope was then advanced into the cyst itself, and a second, basal fenestration was cut toward the prepontine cistern, carefully avoiding the hypothalamus, the perforating arteries, and the basilar artery complex. The result was a wide, permanent three-way channel linking ventricle, cyst, and basal cisterns, allowing trapped cerebrospinal fluid to circulate naturally once again.

The choice of a dual fenestration over simpler alternatives was deliberate and grounded in both anatomy and circumstance. Ventriculocystostomy alone, which opens only the upper membrane, is technically simpler and can suffice for smaller cysts, but in large cysts extending inferiorly toward the prepontine cistern it may fail to restore communication with the basal fluid spaces, leaving the cyst isolated or allowing the stoma to reclose. Endoscopic third ventriculostomy, which bypasses obstruction by creating a hole in the ventricular floor, addresses hydrocephalus but not the cyst’s mass effect. Pediatric series comparing the two techniques have suggested lower recurrence and reoperation rates for the dual approach in appropriately selected patients, echoing early endoscopic principles that favored fenestration into both the ventricle and the basal cisterns. In this boy, whose MRI showed a combined ventricle–cyst–cistern problem rather than isolated aqueductal obstruction, the dual strategy was the anatomically rational one.

There was also a pragmatic dimension to avoiding a shunt. Shunt-based cerebrospinal fluid diversion, the historical mainstay for cyst-related hydrocephalus, imposes lifelong device dependence, and shunts carry clinically meaningful risks of infection and mechanical malfunction that frequently demand revision surgery and ongoing surveillance. In a conflict-affected, resource-limited environment where reliable follow-up, urgent revision capacity, and sterile resources cannot be assumed, those risks are amplified. A definitive, shunt-sparing endoscopic solution that restores natural fluid pathways is therefore not merely a technical preference but a strategy for reducing downstream morbidity where continuity of care is uncertain. Reports from such settings remain relatively scarce, which gives this case particular practical relevance for neurosurgeons working where healthcare infrastructure is fragile.

The outcome, at least in the short term, was encouraging. The child spent twenty-four hours in the neurosurgical intensive care unit, remained fully alert with no new neurological deficits, and early postoperative CT confirmed the fenestration trajectory without hemorrhage or ischemia. A temporary external ventricular drain, placed to manage pressure while the fluid pathways adapted, was removed without incident. A transient dip in adrenal function was detected biochemically and treated with hydrocortisone, normalizing on follow-up testing. He was discharged on the fourth postoperative day with a normal neurological examination and, remarkably, a marked subjective improvement in balance. At three months, MRI showed a reduced cyst size and an improved ventricular configuration, and his balance continued to improve.

Yet the authors are careful to temper optimism with caution. Three months is a short interval for a pediatric suprasellar arachnoid cyst treated endoscopically, and long-term follow-up series show that endocrine abnormalities can evolve over years even when initial testing is normal. The team has arranged structured surveillance across neurosurgery, ophthalmology, and endocrinology, with interval imaging planned at approximately twelve months, to confirm durable decompression and watch for delayed visual, hormonal, or radiological recurrence. They also emphasize that their strategy should not be generalized indiscriminately: surgical decisions must be individualized according to patient age, ventricular size, cyst morphology, membrane configuration, the mechanism of hydrocephalus, and the available equipment and endoscopic expertise. In other anatomical or clinical settings, single fenestration, third ventriculostomy, combined procedures, or shunts may remain the right choice.

The broader lessons of this case reach far beyond one operating room. Children with progressive gait disturbance or subtle signs of raised intracranial pressure warrant timely MRI review for treatable obstructive lesions, because the differential diagnosis includes lesions that a timely operation can cure. Optic disc pallor, even when visual acuity is perfect, should trigger expedited treatment and structured neuro-ophthalmic surveillance, since acuity alone can mask irreversible optic nerve injury. And where shunt maintenance and follow-up reliability are limited, anatomy-based endoscopic fenestration offers a rational path to restoring cerebrospinal fluid dynamics without implanting hardware that a fragile health system may struggle to maintain. A seven-year diagnostic delay nearly cost this boy his sight and his mobility; a single endoscopic procedure, guided by careful anatomy and pragmatic judgment, gave him both back.

Subject of Research: Endoscopic ventriculocystocisternostomy for a giant suprasellar arachnoid cyst with delayed diagnosis and obstructive hydrocephalus in a child

Article Title: Seven‐Year Delayed Diagnosis of a Giant Suprasellar Arachnoid Cyst Presenting With Progressive Gait Disturbance: Successful Endoscopic Ventriculocystocisternostomy—A Case Report

Article References: Ibrahem, Z., Almjersah, A., Mouselli, A., Saleh, I. I., & Alromhain, B. (2026). Seven‐Year Delayed Diagnosis of a Giant Suprasellar Arachnoid Cyst Presenting With Progressive Gait Disturbance: Successful Endoscopic Ventriculocystocisternostomy—A Case Report. Clinical Case Reports, 14(10), Article e73681. https://doi.org/10.1002/ccr3.73681

Image Credits: AI Generated

DOI: 10.1002/ccr3.73681

Keywords: suprasellar arachnoid cyst, obstructive hydrocephalus, neuroendoscopy, ventriculocystocisternostomy, optic disc pallor, gait disturbance, cerebrospinal fluid, pediatric neurosurgery, third ventricle, shunt-sparing surgery, delayed diagnosis, conflict-affected healthcare

Taylor directs the Pediatric Brain Tumor Research Program at Texas Children’s Cancer and Hematology Center and serves as a professor of pediatrics and neurosurgery at Baylor College of Medicine. He is also a CPRIT Scholar in Cancer Research and holds the Cyvia and Melvyn Wolff Chair of Pediatric Neuro-Oncology at Texas Children’s. His dual identity as an operating surgeon and a laboratory scientist is central to the recognition. Few researchers in pediatric oncology occupy both worlds at once, and Taylor’s career has been built on the conviction that the operating theater and the laboratory must inform each other if children with malignant brain tumors are to receive treatments that are both more effective and less damaging to their developing brains.

The scientific core of Taylor’s work lies in two of the most challenging diagnoses in pediatric neuro-oncology: medulloblastoma and ependymoma. Medulloblastoma, the most common malignant brain tumor of childhood, arises in the cerebellum and has long been treated with a blunt combination of surgical resection, craniospinal radiation, and chemotherapy. Ependymoma, which arises from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord, presents its own stubborn clinical problems, particularly in young children in whom radiation must be used sparingly. Taylor and his collaborators have helped establish that medulloblastoma is not a single disease but a collection of biologically distinct entities, a reframing that has reshaped how these tumors are studied, classified, and treated around the world.

That conceptual shift matters enormously in practice. When a tumor once treated uniformly is understood to comprise several molecularly defined subgroups, each with distinct cells of origin, signaling pathways, and clinical behavior, the door opens to therapies aimed at the specific biology driving an individual child’s cancer rather than at the tumor’s location alone. Taylor’s laboratory has pursued this logic by investigating how disruptions in early brain development can set the stage for malignancy, and by exploring potential ways to intervene in the processes that drive tumor growth. The developing brain is a landscape of rapidly dividing progenitor cells and precisely choreographed differentiation programs, and cancers of childhood are increasingly understood as diseases in which these developmental programs are hijacked rather than simply damaged.

Methodologically, Taylor’s team combines genetic analysis, computational tools, and laboratory studies to uncover how childhood brain tumors begin and progress. This triad reflects the modern architecture of cancer research: genomic sequencing and related assays generate dense molecular portraits of tumors, computational biology extracts patterns and candidate vulnerabilities from those portraits, and experimental systems in the laboratory test whether the inferred mechanisms can be perturbed to therapeutic effect. The ultimate aim is to identify treatment approaches that improve survival while reducing the long-term effects that children can experience from existing therapies, an especially urgent concern in a population whose brains are still under construction at the time of treatment.

The stakes of that last goal are difficult to overstate. Children who survive malignant brain tumors frequently carry lifelong consequences of the very treatments that saved them, including cognitive impairment, endocrine dysfunction, and the cumulative toll of radiation to the developing nervous system. A therapeutic landscape built on molecular targeting rather than maximal cytotoxicity promises not only better cure rates but better lives after cure. Taylor’s stated goal of translating discoveries about tumor biology into more effective, targeted treatments speaks directly to this dual mandate, and it is a framing that colleagues at Texas Children’s and Baylor have repeatedly emphasized in describing his contribution to the field.

The institutional context of the award is itself part of the story. “The best place in the entire world right now to do high-quality cancer research is the Texas Medical Center,” Taylor said in remarks accompanying the announcement. “A critical mass of clinicians and scientists, with the world’s best technology and positive Texan attitudes. I look forward to seeing what we do in the near future.” The Texas Medical Center in Houston is the largest medical complex in the world, and the co-location of basic research institutes, clinical trial infrastructure, and one of the highest-volume pediatric neurosurgery services anywhere creates conditions in which laboratory discoveries can move toward patients with unusual speed.

Colleagues framed the award in similarly collaborative terms. “Every child with a brain tumor deserves treatments that are more effective and less toxic,” said Dr. Huda Zoghbi, founding director of the Duncan Neurological Research Institute at Texas Children’s and a Distinguished Service Professor and Howard Hughes Medical Institute Investigator at Baylor College of Medicine. “Dr. Taylor has dedicated his career to that goal, and with CPRIT’s generous support and the collaborative environment at Baylor College of Medicine and Texas Children’s Hospital, his work is reaching patients faster.” Zoghbi’s own standing in neuroscience research lends weight to the assessment, and her emphasis on the pipeline from discovery to patients captures what CPRIT funding has been designed to accelerate across the state.

Dr. Tammy Kang, Interim Director of the Texas Children’s Cancer and Hematology Center and Interim Chief of the Division of Hematology-Oncology in the Department of Pediatrics at Baylor College of Medicine, described the honor as a recognition of leadership as much as science. “This award recognizes Dr. Michael Taylor’s vision, scientific leadership, and commitment to improving outcomes for children with brain tumors,” Kang said. “Dr. Taylor has dedicated his career to advancing our understanding of these devastating diseases and translating discoveries into more effective, personalized therapies for patients. We are proud to see his innovative work supported by CPRIT, and we look forward to the impact this research will have for children and families facing brain cancer in Texas and beyond.”

CPRIT, created by a statewide ballot initiative and sustained by legislative reauthorization, has become one of the largest public cancer research funding mechanisms in the United States, and the Texans Conquer Cancer Award now extends its mission from funding to recognition. For the pediatric brain tumor community, the selection of Taylor as one of the first four honorees signals that childhood brain cancers, long underrepresented relative to adult malignancies in research investment, are being treated as a scientific priority in Texas. For the children and families whose tumors his program studies, the award is a marker of momentum: a surgeon-scientist who has spent his career mapping the biology of medulloblastoma and ependymoma now carries an institutional endorsement that his laboratory’s findings are positioned to reach the bedside, where the need for gentler, smarter cures remains one of the most pressing unsolved problems in all of oncology.

Subject of Research: Recognition of pediatric brain tumor research on medulloblastoma and ependymoma through the Texans Conquer Cancer Award

Article Title: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research

Article References: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Michael Taylor, CPRIT, Texas Children's Hospital, pediatric brain tumors, medulloblastoma, ependymoma, Baylor College of Medicine, pediatric neurosurgery, cancer research funding, Texans Conquer Cancer Award, pediatric oncology, Texas Medical Center

A new multicenter study led by Seifollah Gholampour of the University of Chicago Medicine and David F. Bauer of Texas Children’s Hospital, published in the Annals of Biomedical Engineering, tackles precisely this problem. Drawing on 150 pediatric patients treated at four major U.S. hospitals—Boston Children’s Hospital, Cedars-Sinai Medical Center, Oregon Health & Science University’s Doernbecher Children’s Hospital, and Texas Children’s Hospital—the research team assembled a dataset of 34 clinical, demographic, and imaging variables for each child. They then ran a head-to-head competition: traditional penalized statistical inference, in the form of ridge regression and generalized additive models, against nine cost-sensitive machine learning classifiers, with the best performers combined into a stacked ensemble. Crucially, they wrapped the winning model in an explainable artificial intelligence framework so that its reasoning could be inspected rather than taken on faith.

The results were striking. The stacked ensemble achieved an accuracy and macro-F1 score of 0.77 on held-out test data, with stable generalization across validation folds. More telling was the comparison of discrimination, the model’s ability to separate children who would need surgery from those who would not. For cranial surgery, the ensemble’s area under the receiver operating characteristic curve reached 0.78, compared with just 0.68 for the generalized additive model baseline. For spinal surgery the gap was similar: 0.76 versus 0.66. Calibration, meaning the alignment between predicted probabilities and observed outcomes, was acceptable, and decision curve analysis showed positive net benefit across clinically relevant thresholds for both outcomes. In practical terms, the machine learning approach made meaningfully fewer errors in the scenarios that matter most for surgical planning.

Why should a modestly larger cohort than a traditional statistician might demand still favor machine learning? The answer lies in the structure of the data itself. Rare diseases produce small, class-imbalanced datasets in which only a fraction of patients undergo surgery, and the relationships between predictors and outcomes are rarely linear or independent. A foramen magnum that is critically narrow may matter far more in an infant with hydrocephalus than in an older child without it. Achondroplasia’s phenotype, driven by a well-characterized mutation in the FGFR3 gene, produces a constellation of interacting features—frontal bossing, sleep-disordered breathing, Chiari malformation, back pain—whose joint effects defy simple additive models. Ensemble classifiers, which combine many weak learners, are built to capture such nonlinear dependencies and interactions, provided their outputs can be made transparent enough for clinicians to trust.

Transparency came through SHAP, or SHapley Additive exPlanations, a technique rooted in cooperative game theory that assigns each predictor a contribution value for every individual prediction. When the researchers applied SHAP to the best-performing model, the resulting explanations mapped closely onto clinical intuition while also revealing subtleties that conventional inference had missed. For cranial surgery, the dominant drivers were foramen magnum stenosis, hydrocephalus, family history, frontal bossing, sleep disturbance, and age. For spinal surgery, the leading contributors were spinal stenosis, Chiari malformation, family history, back pain, foramen magnum stenosis, and age. These class-specific profiles matter because they tell surgeons not merely what the model got right, but which features of a given child’s presentation pushed the prediction toward or away from intervention.

Perhaps the most scientifically interesting finding concerns age. In the classical inferential baselines, age did not reach statistical significance as a standalone predictor. Yet SHAP dependence patterns showed that the model attributed importance to age in a context-dependent way: the effect of age on surgical risk depended on whether a child had foramen magnum or spinal stenosis, rather than acting as an independent risk factor. This is exactly the kind of interaction a linear or additive model is designed to smooth away, and its recovery illustrates why the authors argue that explainable machine learning captures clinically contextualized predictive structure that penalized inference can obscure.

The comparison also exposed a provocative asymmetry. Several predictors highlighted prominently by SHAP—sleep disturbance, back pain, and age—were statistically nonsignificant in the inferential baselines. To a traditional biostatistician, that discrepancy might look like a red flag; to the study’s authors, it is evidence that the two frameworks answer different questions. Penalized inference asks which variables show a population-average marginal association, subject to strict regularization and significance testing. The ensemble-plus-SHAP pipeline asks which variables shift individualized risk estimates, including through interactions. Both perspectives carry information, and the study’s dual-stream benchmark was deliberately designed to make that contrast explicit and reproducible rather than to declare a single winner.

The stakes of getting these predictions right are high. Achondroplasia affects roughly one in every 20,000 to 30,000 births worldwide, and its neurosurgical complications have historically driven much of its excess mortality. Compressed brainstem and upper cervical cord in infants can cause central apnea and sudden death, while progressive spinal stenosis in older children can lead to irreversible neurological deficits. Kaplan–Meier analyses in the new study showed that children the model classified as high-risk underwent surgery significantly earlier than those in lower-risk strata, suggesting that the model’s risk scores align with real clinical timelines. A validated preoperative prediction tool could therefore help standardize referral patterns across the handful of specialized skeletal dysplasia centers that handle these cases, and could help families and clinicians structure surveillance schedules around quantified risk rather than intuition alone.

The study is also notable for how honestly it confronts the limitations of machine learning in rare-disease settings. The literature on medical AI is littered with models that report glittering cross-validation numbers but fail on external data, a problem amplified when event counts per variable fall below classical thresholds. The authors addressed class imbalance with cost-sensitive learning rather than naive synthetic oversampling, an approach consistent with their own prior work questioning the clinical validity of techniques like SMOTE on medical data. They evaluated not only discrimination but also calibration and clinical decision curves, and they compared nine candidate classifiers against a proper inferential baseline rather than a straw man. The centralized ethics approval across all four participating institutions, with de-identified retrospective data, allowed a cohort size that no single center could have assembled.

What emerges is less a finished clinical tool than a template for how predictive modeling should be done when data are scarce, imbalanced, and phenotypically messy. By benchmarking statistical inference against explainable AI under explicit rare-disease constraints, and by insisting that every prediction come with a decomposition of its drivers, the team has produced a reproducible framework that other rare-disease researchers can adapt. For children with achondroplasia, the near-term hope is that risk stratification for foramen magnum decompression and spinal surgery becomes earlier, more consistent, and better communicated. For the broader field of clinical machine learning, the message is sharper still: in rare disease, the models that earn clinical trust will not be the most accurate black boxes, but the ones whose reasoning surgeons can read, question, and act upon.

Subject of Research: Explainable AI versus statistical inference for predicting craniospinal surgery in pediatric achondroplasia

Article Title: Predicting Craniospinal Surgery in Pediatric Achondroplasia: Benchmarking Statistical Inference and Explainable AI Under Rare-Disease Constraints

Article References: Gholampour, S., Huang, J., Keusch, D., Lopes, C., Masarwy, A., Obayashi, J., Ruppert-Gomez, M., Sayama, C. M., Baird, L. C., Danielpour, M., & Bauer, D. F. (2026). Predicting Craniospinal Surgery in Pediatric Achondroplasia: Benchmarking Statistical Inference and Explainable AI Under Rare-Disease Constraints. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04352-x

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04352-x

Keywords: achondroplasia, pediatric neurosurgery, explainable AI, SHAP, machine learning, foramen magnum stenosis, spinal stenosis, surgical risk prediction, clinical decision support, rare disease, generalized additive models, Annals of Biomedical Engineering